Flow diagram of Coronary Artery Bypass Graft-Acute Coronary Syndrome (CABG-ACS) trial. Flow diagram of Coronary Artery Bypass Graft-Acute Coronary Syndrome.

Slides:

Advertisements

Similar presentations

1. The term of “ACS” means: (A) Acute cholecystitis symptom (B) Abnormal cerebral signal (C) Abdominal contusion syndrome (D) Acute coronary syndrome.

Advertisements

Date of download: 6/21/2016 Copyright © The American College of Cardiology. All rights reserved. From: Cardiovascular Imaging Research at the Crossroads.

Glenn N. Levine et al. JACC 2016;68:

by Nadine Martel, James Lee, and Philip S. Wells

Early Invasive Versus Initial Conservative Strategies for Women with Non–ST-Elevation Acute Coronary Syndromes: A Nationwide Analysis Islam Y. Elgendy,

MACE rate among CAD severity groups (total 0

TRIAL HIGHLIGHT FROM ESC 2016: ACUTE CORONARY SYNDROMES

Effect of PCI on 1-year risk of all-cause mortality and major cardiovascular outcomes. CABG, coronary artery bypass grafting; CI, confidence interval (bars);

% Heparin + GPI IIb/IIIa Bivalirudin +

Hazard ratios for the composite primary end-point from sub-group analyses of patents presenting with and without an acute coronary syndrome. Hazard ratios.

Juan A. Crestanello, MD, Richard C. Daly, MD

Three-Year Outcomes of Multivessel Revascularization in Very Elderly Acute Coronary Syndrome Patients Brett C. Sheridan, MD, Sally C. Stearns, PhD, Joseph.

Defining operative mortality: Impact on outcome reporting

Coronary revascularisation rate (total 5

Any and definite stent thrombosis (ST) and in-device late lumen loss (LLL) with bioresorbable vascular scaffold (BVS) versus drug-eluting stent (DES) in.

CT angiography results (vertical axis, N=count of patients): (A) total Coronary Calcium Score (CCS) (y-axis, Agatston Score), (B) coronary stenosis severity.

Flow chart of the study population according to thienopyridines used in the FAST-MI registry in patients with STEMI and NSTEMI. FAST-MI, French Registry.

Kaplan-Meier curves: revascularisation rate (PCI or CABG) was significantly higher (p

Kaplan-Meier estimate of mortality in 1798 propensity score matched pairs with a propensity score >0.5 for the whole observational period. Kaplan-Meier.

Flow Diagram of the Trial Selection Process

(A) Meta-analysis of repeat revascularisation in randomised trials.

Death, target vessel revascularisation (TVR) and myocardial infarction (MI) with bioresorbable vascular scaffold (BVS) versus drug-eluting stent (DES)

SOLID-TIMI 52 Trial design: Participants within 30 days of an acute coronary syndrome (ACS) were randomized to darapladib 160 mg daily (n = 6,504) versus.

Long-term results estimates for patients with anomalous origin of coronary artery from the pulmonary artery, showing survival, freedom from coronary and.

Forest plots of randomised controlled trials and propensity score matched studies examining outcomes between patients taking proton pump inhibitor (PPIs)

Kaplan–Meier survival curve for major adverse cardiac events (MACE): a trend towards superior survival in patients without signs of coronary artery disease.

Algorithm for the investigation of patients with elevated cardiac troponin concentrations in the context of an alternative acute illness. Algorithm for.

Asymptomatic 67-year-old man prior to orthopaedic surgery with three cardiac risk factors and borderline ST-segment depression inferior-posterior on treadmill.

(A) Multivariable Cox regressions showing the association of higher CHA2DS2-Vasc scores (≥6) and (B) R2CHA2DS2-Vasc scores (≥7) with 1-year mortality (CABG,

Cox regression of proportion mortality in the first 8 years for patients with three-vessel disease with a significant difference between the treatment.

Hierarchical clustering analysis of 7785 genes (genes with a log-ratio variation in the 25th centile and >5% missing data were excluded) (A) A heat map.

(A) Quantitative plaque analysis of the RCA

Change in 6 min walk distance from baseline to each follow-up time for subjects randomised to CABG and to medical therapy alone. The median change and.

Screening for fibromuscular dysplasia (FMD).

Flow chart showing reinterventions by type in patients with anomalous origin of coronary artery from the pulmonary artery patients, divided into early.

Glenn N. Levine et al. JACC 2011;58:e44-e122

Kaplan–Meyer survival curve of 1313 patients following primary PCI

Correlation of calibrated integrated backscatter (cIB) with log10 total fibrosis (A) and log10 interstitial fibrosis (B) in patients undergoing coronary.

Correlations of calibrated integrated backscatter (cIB) with log10 plasma soluble vascular endothelial growth factor receptor-1 (sVEGFR-1) (A), and log10.

ASCOT: randomised trial showing a decrease in cardiovascular mortality in patients treated with amlodipine/perindopril compared with atenolol/thiazide.

Figures showing the effects of a potential 30% relative reduction in events with next-generation drug-eluting stents in the percutaneous coronary intervention.

Flow chart of the cohort selection for the study

Representative images of coronary angiography and fractional flow reserve (FFR) from a patient who showed no resting ECG abnormality. Representative images.

Antithrombotic strategies in patients on long-term oral anticoagulation therapy undergoing percutaneous coronary intervention. ACS: acute coronary syndrome;

Leslee J. Shaw et al. JIMG 2010;3:

Number of patients who would have benefitted from addition of ACE inhibitor (ACEi), beta blockers (BB) or optimal therapy (one or both of ACEi and BB)

Illustration of a trial design to help evaluate the clinical accuracy of a test of ischaemia. Illustration of a trial design to help evaluate the clinical.

Cost-effectiveness plane for all PARTNER-B vs all ADVANCE and all PARTNER vs ADVANCE high risk comparisons with ICERs from five studies; dashed line represents.

A model of variation and accelerating factors in the process of acute care chain of patients with STEMI going for primary PCI. PCI, percutaneous coronary.

Baseline characteristics of study population

Forest plot of studies examining outcomes between patients taking proton pump inhibitor (PPIs) with clopidogrel and those taking only clopidogrel: (A)

Decision tree (using the CHAID algorithm) for predicting participation in a cardiac prevention and rehabilitation programme (CPRP) among 420 Jewish and.

Summary of STICH trial patients included in the analysis of 6 min walk distance. Reasons for non-inclusion at each follow-up time are given. CABG, coronary.

Effect of PCI on 3 to 5-year risk of all-cause mortality and major cardiovascular outcomes. CABG, coronary artery bypass grafting; CI, confidence interval.

Result of coronary angiogram among patients with and without diabetes admitted with first-time acute coronary syndrome (a significant stenosis was defined.

Major bleeding with bivalirudin versus unfractionated heparin (UFH) in predominantly non-ST segment elevation acute coronary syndrome (NSTE-ACS) studies;

Kaplan-Meier estimate of mortality in the two treatment strategies with significant difference between the two groups (log-rank test

Use of evidence-based cardiac medications before, during and after hospitalisation for the index event in (A) overall ACS population and (B) patients with.

Heat map of microRNA microarray expression from the four groups of patients. Heat map of microRNA microarray expression from the four groups of patients.

Multivariable-adjusted HRs and 95% CIs for outcomes for waist circumference. Multivariable-adjusted HRs and 95% CIs for outcomes for waist circumference.

Hazard ratios for the composite primary end-point from sub-group analyses of patents presenting with and without an acute coronary syndrome. Hazard ratios.

P2Y12 receptor inhibitor therapy for secondary prevention of patients with stable coronary artery disease. P2Y12 receptor inhibitor therapy for secondary.

Performance of the Manchester Acute Coronary Syndromes decision rule with high-sensitivity cardiac troponin T (hs-cTnT) as the reference standard for the.

Performance of the Manchester Acute Coronary Syndromes decision rule in the validation study. Performance of the Manchester Acute Coronary Syndromes decision.

Flow diagram of study conduct.

FFR guided deferral of PCI in patients with ACS and stable coronary artery disease (SCAD). FFR guided deferral of PCI in patients with ACS and stable coronary.

Change in 6 min walk distance at 12 months in subgroups defined by baseline characteristics. The mean (95% CI) for the difference between CABG and medical.

The Ottawa COPD (chronic obstructive pulmonary disease) Risk Scale (OCRS) is used in the emergency department (ED) to identify patients with acute COPD.

Proposed future revascularisation strategy in patients with ESRD based on our current results and previous guideline recommendations. Proposed future revascularisation.

Study flow chart and diagnosis at discharge from ED

Presentation transcript:

Flow diagram of Coronary Artery Bypass Graft-Acute Coronary Syndrome (CABG-ACS) trial. Flow diagram of Coronary Artery Bypass Graft-Acute Coronary Syndrome (CABG-ACS) trial. Patients who provide consent will enter either the (1) randomised trial or (2) registry (ie, based on the presence of exclusion criteria, or physician or patient preference). Patients who do not provide consent and/or are ineligible will enter the (3) screen failure group. A change in the treatment strategy (eg, from non-invasive to invasive management, or vice versa) within the first 30 days from randomisation is a cross-over. Matthew M Y Lee et al. Open Heart 2016;3:e000371 ©2016 by British Cardiovascular Society